July 05, 2018: Santhera to Present Novel Data Highlighting the Clinical Relevance of Peak Expiratory Flow as Predictor of Disease Progression in Duchenne Muscular Dystrophy

June 22, 2018: UK’s MHRA renews Early Access to Medicines Scheme Scientific Opinion for Santhera’s Raxone^® (idebenone) in Duchenne Muscular Dystrophy

June 12, 2018: Santhera Submits NDA in South Korea for Raxone^® for the Treatment of LHON

April 12, 2018: Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting

April 05, 2018: Santhera Announces Successful Completion of First Clinical Trial with Omigapil in Patients with Congenital Muscular Dystrophy

March 20, 2018: Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy

March 05, 2018: Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH

February 22, 2018: Santhera Completes Capital Increase to Settle Obtained License from Polyphor

February 15, 2018: Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases

February 06, 2018: Santhera Launches U.S. Expanded Access Program with Idebenone for Patients with Duchenne Muscular Dystrophy (DMD)

January 29, 2018: Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update

Conference Call 14:00 hrs CET (audio file mp3)

January 26, 2018: Santhera Receives Negative CHMP Opinion on Appeal for Authorization of Raxone^® in Duchenne Muscular Dystrophy

Conference Call 14:00 hrs CET (audio file mp3)

January 24, 2018: Santhera Anticipates Receiving a Negative CHMP Opinion on Appeal for Marketing Authorization Application for Raxone^® in Duchenne Muscular Dystrophy

January 19, 2018: Santhera Plans to Announce Regulatory Feedback for Raxone^® in DMD and 2017 Preliminary Key Financial Figures